Pirfenidone in heart failure with preserved ejection fraction—rationale and design of the PIROUETTE trial
<p><strong>Background</strong></p> <p>The PIROUETTE (PIRfenidOne in patients with heart failUre and preserved lEfT venTricular Ejection fraction) trial is designed to evaluate the efficacy and safety of the anti-fibrotic pirfenidone in patients with chronic heart failur...
Auteurs principaux: | Lewis, G, Schelbert, E, Naish, J, Bedson, E, Dodd, S, Eccleson, H, Clayton, D, Jimenez, B, McDonagh, T, Williams, S, Cooper, A, Cunnington, C, Ahmed, F, Viswesvaraiah, R, Russell, S, Neubauer, S, Williamson, P, Miller, C |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
Springer Nature
2019
|
Documents similaires
-
Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone
par: Gavin A. Lewis, et autres
Publié: (2022-07-01) -
Pirouette.
par: T. T. Cloete
Publié: (2017-03-01) -
Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction
par: Francesca Graziani, et autres
Publié: (2021-04-01) -
Pirouette : spinner of power.
par: Patrick, Brian, author
Publié: (1997) -
György Faludy. <i>Silver Pirouettes.</i> Trans. Paul Sohar.
par: Péter Hargitai
Publié: (2016-01-01)